Mazyar Shadman, MD, MPH, and Brian T. Hill, MD, PhD, discuss the importance of CD19-targeted therapy as a promising option in the relapsed/refractory DLBCL setting.
September 15th 2021
Mazyar Shadman, MD, MPH, and Brian T. Hill, MD, PhD, explain the intricacies of the diffuse large B-cell lymphoma treatment landscape.
The experts delve further into treatment methods for relapsed/refractory diffuse large B-cell lymphoma, particular for transplant-eligible and -ineligible patients.
September 22nd 2021
Drs Shadman and Hill discuss using CD19 as a targeted therapy option in CAR T cell therapy for relapsed/refractory diffuse large B-cell lymphoma.
Dr Mazyar Shadman and Dr Brian T. Hill focus on CD19 being targeted in monoclonal antibody therapy options for relapsed/refractory diffuse large B-cell lymphoma, specifically tafasitamab.
September 30th 2021
The discussion of tafasitamab as a monoclonal antibody therapy option for relapsed/refractory diffuse large B-cell lymphoma continues.
The doctors switch their monoclonal antibody conversation’s focus to longcastuximab tesirine for the treatment of relapsed/refractory diffuse large B-cell lymphoma.
October 6th 2021
Two experts examine bispecific antibody treatment use for relapsed/refractory diffuse large B-cell lymphoma.
Mazyar Shadman, MD, MPH, and Brian T. Hill, MD, PhD, consider potential treatment options for relapsed/refractory diffuse large B-cell lymphoma in the future.